Tango Therapeutics (TNGX) Capital Expenditures (2020 - 2026)
Tango Therapeutics (TNGX) posted quarterly Capital Expenditures of -$10000.0 for Q1 2026, down 119.61% year-over-year from $51000.0 in Q1 2025, and down 112.99% quarter-over-quarter from $77000.0 in Q4 2025.
Tango Therapeutics (TNGX) Capital Expenditures (2020 - 2026) Analysis & Trends
Tango Therapeutics' Capital Expenditures history runs 7 years deep, the most recent figure standing at -$10000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures fell 119.61% year-over-year to -$10000.0; the TTM figure through Mar 2026 stood at $238000.0 (down 71.67% YoY), while the FY2025 annual figure was $299000.0, down 60.34% from the prior year.
- Capital Expenditures for Q1 2026 stood at -$10000.0, down from $77000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $6.7 million in Q3 2022, with the low at -$1.3 million in Q4 2023.
- The 5-year median for Capital Expenditures is $77000.0 (2025), against an average of $516058.8.
- The sharpest annual moves came in 2022 and 2024: Capital Expenditures soared 1448.6% in 2022, then slumped 3531.25% in 2024.
- Tango Therapeutics' Capital Expenditures stood at $1.0 million in 2022, then slumped by 221.23% to -$1.3 million in 2023, then jumped by 162.44% to $788000.0 in 2024, then sank by 90.23% to $77000.0 in 2025, then slumped by 112.99% to -$10000.0 in 2026.
- Business Quant data shows TNGX's Capital Expenditures at -$10000.0 in Q1 2026, $77000.0 in Q4 2025, and -$84000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - | 150,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 150,000.00 |
| Jun 30, 2026 | 150,000.00 |
| Mar 31, 2026 | -10,000.00 |
| Mar 31, 2026 | -10,000.00 |
| Dec 31, 2025 | 77,000.00 |
| Dec 31, 2025 | 77,000.00 |
| Sep 30, 2025 | -84,000.00 |
| Sep 30, 2025 | -84,000.00 |
| Jun 30, 2025 | 255,000.00 |
| Jun 30, 2025 | 255,000.00 |
| Mar 31, 2025 | 51,000.00 |
| Mar 31, 2025 | 51,000.00 |
| Dec 31, 2024 | 788,000.00 |
| Dec 31, 2024 | 788,000.00 |
| Sep 30, 2024 | -549,000.00 |
| Sep 30, 2024 | -549,000.00 |
| Jun 30, 2024 | 550,000.00 |
| Jun 30, 2024 | 550,000.00 |
| Mar 31, 2024 | -35,000.00 |
| Mar 31, 2024 | -35,000.00 |